CMC Director since 2013
Martin Scobie received a PhD in chemistry from the University of Edinburgh. After post-doctoral studies in Switzerland and the UK, he was recruited by the start-up company Oxford Diversity PLC where he worked as project leader, gaining commercial and project management experience on a number of successful programs. After relocating to Sweden he worked with Pharmacia AB, Biovitrum AB and Orexo AB in senior scientist and team leader roles. In 2010 he was recruited by Professor Thomas Helleday to recruit and lead a medicinal chemistry team based at Karolinska Institutet. The team is focused on developing inhibitors to novel targets involved in DNA repair and metabolism. Since 2013 Martin has been closely involved in CMC and pharmaceutical development of Karonudib (Oxcia’s MTH1 inhibitor), and the discovery of other small molecule inhibitors in Oxcia’s pipeline.
Holdings: 0 A-shares, 575 000 B-shares and 10 000 warrants